74.19

2.85% -2.18

Nektar Therapeutics (NKTR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Nektar Therapeutics stock is traded at $74.19, with a volume of 601.54K. It is down -2.85% in the last 24 hours and up +1.97% over the past month. Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

Previous Close:

$76.37

Open:

$74.67

24h Volume:

601.54K

Relative Volume:

0.66

Market Cap:

$2.53B

Revenue:

$55.63M

Net Income/Loss:

$-158.10M

P/E Ratio:

-8.811

EPS:

-8.4202

Net Cash Flow:

$-203.94M

1W Performance:

+2.30%

1M Performance:

+1.97%

6M Performance:

+4.33%

1Y Performance:

+106.20%

1-Day Range:

$73.64

$75.63

1-Week Range:

$70.00

$76.63

52-Week Range:

$33.40

$109.00

Nektar Therapeutics Stock (NKTR) Company Profile

Name

Nektar Therapeutics

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(415) 482-5300

Address

455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA

Employee

Twitter

@nektarnews

Next Earnings Date

2026-08-13

Latest SEC Filings

NKTR's Discussions on Twitter

Compare NKTR vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NKTR Nektar Therapeutics	74.19	2.54B	55.63M	-158.10M	-203.94M	-8.4202
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-24-26	Initiated	Wedbush	Neutral
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy
Jun-24-25	Reiterated	BTIG Research	Buy
Jun-24-25	Reiterated	H.C. Wainwright	Buy
Apr-11-25	Upgrade	Jefferies	Hold → Buy
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform
Jan-08-25	Initiated	B. Riley Securities	Buy
Dec-10-24	Initiated	H.C. Wainwright	Buy
Nov-04-24	Initiated	Piper Sandler	Overweight
Sep-30-24	Resumed	BTIG Research	Buy
Jun-28-24	Initiated	Rodman & Renshaw	Buy
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold
Feb-24-23	Downgrade	Jefferies	Hold → Underperform
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold
Apr-18-22	Downgrade	Goldman	Neutral → Sell
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-15-22	Downgrade	Mizuho	Buy → Neutral
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform
Mar-14-22	Downgrade	Stifel	Buy → Hold
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy
Sep-10-21	Initiated	BofA Securities	Neutral
Jun-28-21	Upgrade	Stifel	Hold → Buy
May-18-21	Resumed	Goldman	Neutral
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold
Sep-14-20	Initiated	JP Morgan	Neutral
Jun-10-20	Downgrade	CFRA	Hold → Sell
May-12-20	Reiterated	H.C. Wainwright	Neutral
Apr-22-20	Initiated	The Benchmark Company	Buy
Mar-30-20	Upgrade	Goldman	Sell → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Feb-03-20	Upgrade	Mizuho	Neutral → Buy
Oct-24-19	Initiated	Oppenheimer	Perform
Oct-08-19	Downgrade	Goldman	Buy → Sell
Aug-09-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-09-19	Downgrade	Jefferies	Buy → Hold
Aug-09-19	Downgrade	Mizuho	Buy → Neutral
Mar-15-19	Initiated	SVB Leerink	Mkt Perform
Dec-13-18	Initiated	Goldman	Buy
Jun-11-18	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-04-18	Reiterated	H.C. Wainwright	Buy
Apr-20-18	Initiated	Seaport Global Securities	Buy
Apr-13-18	Resumed	Piper Jaffray	Overweight
Apr-06-18	Reiterated	Mizuho	Buy
Apr-02-18	Resumed	H.C. Wainwright	Buy

View All

Nektar Therapeutics Stock (NKTR) Latest News

Aug 22, 2026

How Investors Are Reacting To Nektar Therapeutics (NKTR) Q2 Loss, ESOP Shelf Registration And Financing Flexibility - simplywall.st

Aug 22, 2026

Aug 21, 2026

JPMorgan Chase & Co. Initiates Coverage on Nektar Therapeutics (NASDAQ:NKTR) - MarketBeat

Aug 21, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Shareholders to Connect - ACCESS Newswire

Aug 21, 2026

Nektar Therapeutics chief R&D officer Zalevsky sells $13,388 in shares - Investing.com

Aug 21, 2026

Aug 20, 2026

Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock By Investing.com - Investing.com South Africa

Aug 20, 2026

Nektar Therapeutics CEO Howard W. Robin sells $30,087 in stock - Investing.com

Aug 20, 2026

Nektar Therapeutics (NASDAQ:NKTR) Insider Jonathan Zalevsky Sells 186 Shares of Stock - MarketBeat

Aug 20, 2026

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells $30,087.64 in Stock - MarketBeat

Aug 20, 2026

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results - Stocktwits

Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus

Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock News, Headlines & Updates - GuruFocus

Aug 20, 2026

Nektar Therapeutics (XTER:ITH0) Stock Price, Trades & News - GuruFocus

Aug 20, 2026

Aug 19, 2026

Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Moomoo

Aug 19, 2026

Aug 18, 2026

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nektar Therapeutics (NKTR) And Encourages Shareholders to Reach Out - ACCESS Newswire

Aug 18, 2026

Nektar (NASDAQ: NKTR) exec to sell 186 shares, partly for taxes - Stock Titan

Aug 18, 2026

Nektar Therapeutics (NASDAQ: NKTR) insider plans 418-share sale - Stock Titan

Aug 18, 2026

Aug 16, 2026

NKTR Stock Skyrockets: Wall Street Sees Up To 200% Upside As Skin Trial Crushes Even Bull-Case Forecasts - Stocktwits

Aug 16, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Aug 16, 2026

2026-08-16 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Investors to Learn More About the Investigation | NDAQ:NKTR | Press Release - Stockhouse

Aug 16, 2026

Aug 15, 2026